12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga · 07/15 12:07
Gainers
- Longevity Health Holdings (NASDAQ:XAGE) stock rose 127.6% to $6.02 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.6 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 44.46% to $4.78. The market value of their outstanding shares is at $5.2 million.
- Kairos Pharma (AMEX:KAPA) stock rose 40.11% to $0.96. The market value of their outstanding shares is at $11.5 million.
- OKYO Pharma (NASDAQ:OKYO) stock increased by 20.15% to $3.1. The market value of their outstanding shares is at $96.5 million.
- Cadrenal Therapeutics (NASDAQ:CVKD) shares rose 19.43% to $14.93. The market value of their outstanding shares is at $24.5 million.
- 60 Degrees (NASDAQ:SXTP) shares rose 16.85% to $2.53. The company's market cap stands at $3.1 million.
Losers
- Organogenesis Holdings (NASDAQ:ORGO) stock declined by 24.3% to $3.4 during Tuesday's pre-market session. The company's market cap stands at $569.5 million.
- Sonnet BioTherapeutics (NASDAQ:SONN) shares declined by 18.05% to $7.9. The company's market cap stands at $30.5 million.
- Rani Therapeutics Hldgs (NASDAQ:RANI) stock decreased by 17.53% to $0.58. The market value of their outstanding shares is at $27.4 million.
- Burning Rock Biotech (NASDAQ:BNR) stock decreased by 17.5% to $3.82. The company's market cap stands at $47.4 million.
- Talphera (NASDAQ:TLPH) shares decreased by 15.6% to $0.4. The market value of their outstanding shares is at $9.7 million.
- MiNK Therapeutics (NASDAQ:INKT) shares fell 13.82% to $35.0. The market value of their outstanding shares is at $161.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.